Drug policy impacts regional trends of ezetimibe use

June 5, 2014
Drug policy impacts regional trends of ezetimibe use

(HealthDay)—Within Canada, regional variation has been noted in ezetimibe use, which is associated with the restrictiveness of publicly-funded drug formularies, according to a study published online June 3 in Circulation: Cardiovascular Quality and Outcomes.

Lingyun Lu, Pharm.D., from the Western University of Health Sciences in Pomona, Calif., and colleagues conducted a population-level cohort study to examine ezetimibe use in four provinces in Canada. The provinces had a gradient in the restrictiveness of ezetimibe in publicly-funded formularies (most to least restrictive: British Columbia, Alberta, Quebec, and Ontario). Use was examined using IMS Health Canada's data from June 2003 to December 2012.

The researchers observed in ezetimibe use patterns. The lowest monthly increasing rate was seen in British Columbia (most restrictive), which increased from $261 (Canadian dollars) to $21,926 from June 2003 to December 2012 ($190/100,000 population/month). In contrast, the least restrictive Ontario had the most rapid monthly increase, from $223 to $74,030 ($647/100,000 population/month). Quebec and Alberta had intermediate increases, from $130 to $59,690 ($522/100,000 population/month) and from $356 to $37,604 ($327/100,000 population/month), respectively.

"Ezetimibe use remains common, increasing during the past decade," the authors write. "The gradient in use was related to variability in restrictiveness of the provincial formularies, illustrating the potential of a policy response gradient that may be used to more effectively manage medication use."

Several authors disclosed financial ties to the pharmaceutical, medical device, and insurance industries.

Explore further: Significantly improved chance of heart attack survival with high-potency statin treatment

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014
(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking ...

Statins for kidney disease patients: Protection for the heart but no effects on kidneys

May 1, 2014
Lowering LDL cholesterol through statin-based treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The ...

Evolocumab superior to ezetimibe in lowering LDL cholesterol

March 31, 2014
Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable ...

Antibody combined with statin results in further reduction of cholesterol levels

May 13, 2014
Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition of the human monoclonal antibody evolocumab resulted in additional lowering of low-density lipoprotein cholesterol (LDL-C) ...

Elevated cholesterol levels: Benefit of ezetimibe is not proven

September 14, 2011
Elevated blood cholesterol levels are regarded as a risk factor for heart attacks and other cardiovascular diseases. However, this does not necessarily mean that every cholesterol-lowering drug can also prevent heart attacks. ...

Recommended for you

Researchers borrow from AIDS playbook to tackle rheumatic heart disease

January 22, 2018
Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the ...

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.